4//SEC Filing
Zanganeh Mahkam 4
Accession 0001599298-25-000143
CIK 0001599298other
Filed
Sep 10, 8:00 PM ET
Accepted
Sep 11, 7:36 PM ET
Size
10.3 KB
Accession
0001599298-25-000143
Insider Transaction Report
Form 4
Zanganeh Mahkam
DirectorCo-Chief Executive Officer10% Owner
Transactions
- Purchase
Common Stock
2025-09-11$18.07/sh+5,000$90,350→ 556,093,090 total(indirect: By Spouse) - Purchase
Common Stock
2025-09-10$17.68/sh+333,394$5,894,406→ 556,088,090 total(indirect: By Spouse)
Holdings
- 50,000(indirect: Immediate family member)
Common Stock
- 10,199,776(indirect: By Trust)
Common Stock
- 31,000
Common Stock
- 25,457,666(indirect: By Trust)
Common Stock
Footnotes (2)
- [F1]The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $17.49 to $17.89 per share, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F2]The Reporting Person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose
Documents
Issuer
Summit Therapeutics Inc.
CIK 0001599298
Entity typeother
Related Parties
1- filerCIK 0001507650
Filing Metadata
- Form type
- 4
- Filed
- Sep 10, 8:00 PM ET
- Accepted
- Sep 11, 7:36 PM ET
- Size
- 10.3 KB